Plasma Proteome Profiles of Stable CAD Patients Stratified According to Total Apo C-III Levels.
Apo C-III
apolipoproteins
cardiovascular disease
coronary artery disease
plasma proteomics
Journal
Proteomics. Clinical applications
ISSN: 1862-8354
Titre abrégé: Proteomics Clin Appl
Pays: Germany
ID NLM: 101298608
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
05
02
2018
revised:
30
06
2018
pubmed:
12
7
2018
medline:
31
1
2020
entrez:
12
7
2018
Statut:
ppublish
Résumé
The present research reports the study the of plasma proteome profile of stable coronary artery disease (CAD) patients characterized by different levels of total Apolipoprotein-CIII (Apo C-III), a prognostic marker for cardiovascular risk. Two subgroups of CAD patients (n = 52) with divergent concentrations of total circulating Apo C-III (≤ and ≥10 mg dL A total of 188 proteins are quantified among the patients. The fold change analysis and the partial least square discriminant analysis show a clear separation of the two groups. Lipoproteins (Apo C-II and Apo E), retinol-binding protein 4, and vitronectin are upregulated in patients with high Apo C-III, while alpha-1 antitrypsin is downregulated. In this pilot study, the differential expression of plasma proteins related to different concentrations of Apo C-III is defined, suggesting possible new players involved in the Apo C-III-associated process of arterial damage. Data are available via ProteomeXchange with identifier PXD005973.
Identifiants
pubmed: 29992792
doi: 10.1002/prca.201800023
doi:
Substances chimiques
Apolipoprotein C-III
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1800023Informations de copyright
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.